$EVGN

RECANATI LEON purchased $400K of EVGN

RECANATI LEON purchased 800,000 shares of Evogene Ltd. (EVGN) at $0.50 ($0.40M total) on 2026-08-04.

Original reporting
SEC EDGAR · RECANATI LEON
Published Aug 5, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EVGN
Bullish
medium confidence
Mentioned
$EVGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVGNBullishLow
01

Why it matters

This provides a new, dated insider purchase fact, but it does not include any new corporate event (earnings, trial results, financing, or regulatory action) that would materially reset valuation expectations.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no additional fundamental information in the text.

03

What to watch

The filing does not include whether the director’s broader trading pattern changed, nor any company-specific news that would validate the buy as a new catalyst.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-05 after-hours; transaction dated 2026-08-04

Background

The article is a SEC Form 4 insider transaction disclosure for Evogene Ltd. (EVGN).

Company-level read

Ticker impact

$EVGNBullishMedium confidence
Context

Evogene director Leon Recanati filed an open-market purchase of 800,000 shares at $0.50 on 2026-08-04, totaling $400,000.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the article provides no accompanying company-specific operational update, and the transaction lacks a 10b5-1 plan context.

Market effects

No sector-wide implications; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification rather than a strong forward-looking signal, especially without a stated rationale.

Key entities

  • Evogene Ltd.

    Subject of the Form 4 insider transaction disclosure.

  • RECANATI LEON

    Director who purchased 800,000 shares open-market at $0.50 on 2026-08-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EVGNMed

Evogene Ltd. (EVGN): Financial results for Q2 2026

Evogene Ltd. (EVGN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Evogene Reports Second Quarter and First Half 2026 Financial Results · Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product d